A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

• Status: Terminated
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Adult patients, 19-75 years of age

• Multiple myeloma.

• Progressive disease after at least 2 lines of prior therapy.

Exclusion Criteria:

• Non-secretory myeloma.

• History of malignancy, other than squamous cell cancer, basal cell cancer, or cancer in situ of the cervix within the last 5 years.

• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start.

• Clinically significant cardiac disease.